Xeris Biopharma Holdings, Inc. Stock Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Financials (USD)
Sales 2024 * | 184M | Sales 2025 * | 219M | Capitalization | 261M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -27M | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
-4.57
x | P/E ratio 2025 * |
-9.6
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 04-12-31 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 21-10-04 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
1st Jan change | Capi. | |
---|---|---|
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |